Patterns of breast cancer radiotherapy practices among Saudi radiation oncologists

References

1. 1.↵
   1. McGuire S. World Cancer Report

   2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 2016; 7: 418–419.

   OpenUrl
2. 2.↵
   1. Asiri S,
   2. Asiri A,
   3. Ulahannan S,
   4. Alanazi M,
   5. Humran A,
   6. Hummadi A.

   Incidence rates of breast cancer by age and tumor characteristics among saudi women: recent trends. Cureus 2020; 12: e6664.

   OpenUrl
3. 3.↵
   1. van Maaren MC,
   2. de Munck L,
   3. de Bock GH,
   4. Jobsen JJ,
   5. van Dalen T,
   6. Linn SC, et al.

   10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol 2016; 17: 1158–1170.

   OpenUrl
4. 4.↵
   1. Recht A,
   2. Comen EA,
   3. Fine RE,
   4. Fleming GF,
   5. Hardenbergh PH,
   6. Ho AY, et al.

   Postmastectomy radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. J Clin Oncol 2016; 6: e219–e234.

   OpenUrl
5. 5.↵
   1. Duane FK,
   2. McGale P,
   3. Teoh S,
   4. Mortimer C,
   5. Broggio J,
   6. Darby SC, et al.

   International variation in criteria for internal mammary chain radiotherapy. Clin Oncol 2019; 31: 453–461.

   OpenUrl
6. 6.↵
   1. Duma MN.

   An update on regional nodal irradiation: indication, target volume delineation, and radiotherapy techniques. Breast Care 2020; 15:128–135.

   OpenUrl
7. 7.↵
   1. Nguyen K,
   2. Mackenzie P,
   3. Allen A,
   4. Dreosti M,
   5. Morgia M,
   6. Zissiadis Y, et al.

   Breast interest group faculty of radiation oncology: Australian and New Zealand patterns of practice survey on breast radiotherapy. J Med Imaging Radiat Oncol 2017; 61: 508–516.

   OpenUrl
8. 8.↵
   Saudi Vision 2030. Saudi National Transformation Program, 2016. Saudi Arabia Government [Updated 2021; Cited 2020 November 16]. Available from: https://vision2030.gov.sa/en
9. 9.↵
   1. Althubiti MA,
   2. Nour Eldein MM.

   Trends in the incidence and mortality of cancer in Saudi Arabia. Saudi Med J 2018; 39: 1259–1263.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Almutlaq BA,
    2. Almuazzi RF,
    3. Almuhayfir AA,
    4. Alfouzan AM,
    5. Alshammari BT,
    6. AlAnzi HS, et al.

    Breast cancer in Saudi Arabia and its possible risk factors. J Cancer Policy 2017; 12: 83–89.

    OpenUrl
11. 11.↵
    1. Smith BD,
    2. Bellon JR,
    3. Blitzblau R,
    4. Freedman G,
    5. Haffty B,
    6. Hahn C, et al.

    Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol 2018; 8: 145–152.

    OpenUrlPubMed
12. 12.↵
    1. Morrow M,
    2. Van Zee KJ,
    3. Solin LJ,
    4. Houssami N,
    5. Chavez-MacGregor M,
    6. Harris JR, et al.

    Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. J Clin Oncol 2016; 23: 3801–3810.

    OpenUrl
13. 13.↵
    1. Moran MS,
    2. Zhao Y,
    3. Ma S,
    4. Kirova Y,
    5. Fourquet A,
    6. Chen P, et al.

    Association of radiotherapy boost for ductal carcinoma in situ with local control after whole-breast radiotherapy. JAMA Oncol 2017; 3: 1060–1068.

    OpenUrl
14. 14.↵
    1. Gupta A,
    2. Ohri N,
    3. Haffty BG.

    Hypofractionated radiation treatment in the management of breast cancer. Expert Rev Anticancer Ther 2018; 18: 793–803.

    OpenUrl
15. 15.↵
    1. Laurberg T,
    2. Tramm T,
    3. Nielsen T,
    4. Alsner J,
    5. Nord S,
    6. Myhre S, et al.

    Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy–results from two independent randomized trials. Acta Oncol (Madr) 2018; 38–43.
16. 16.↵
    1. Ejlertsen B,
    2. Offersen BV,
    3. Overgaard J,
    4. Christiansen P,
    5. Jensen MB,
    6. Kroman N, et al.

    Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. Acta Oncol (Madr) 2018; 57: 3–12.

    OpenUrl
17. 17.↵
    The Royal College of Radiologist. Postoperative radiotherapy for breast cancer: UK consensus statements. [Updated 2016 November; Accessed 2020 December 16]. Available from: https://www.rcr.ac.uk/system/files/publication/field_publication_files/bfco2016_breast-consensus-guidelines.pdf
18. 18.↵
    ClinicalTrials.gov [Internet]. Identifier NCT03414970, Hypofractionated radiation therapy after mastectomy in preventing recurrence in patients with stage IIa-IIIa breast cancer. [Updated 2018 January 30. Cited 2020 December 16]. Available from: https://Clinicaltrials.Gov/Show/Nct03414970
19. 19.↵
    ClinicalTrials.gov. Study of radiation Fractionation on patient outcomes after breast REConstruction (FABREC) for invasive breast carcinoma. Identifier NCT03422003. [Updated 2018 February 5; Accessed 2020 December 16]. Available from: https://Clinicaltrials.Gov/Show/Nct03422003.
20. 20.↵
    1. Wang SL,
    2. Fang H,
    3. Song YW,
    4. Wang WH,
    5. Hu C,
    6. Liu YP, et al.

    Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2019; 20: 352–360.

    OpenUrl
21. 21.↵
    1. Kim YJ,
    2. Park W,
    3. Ha B,
    4. Park B,
    5. Joo J,
    6. Kim TH, et al.

    Postmastectomy radiotherapy in patients with pT1-2N1 breast cancer treated with taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418). Cancer Res Treat 2017; 49: 927.

    OpenUrl
22. 22.↵
    1. Velikova G,
    2. Williams LJ,
    3. Willis S,
    4. Dixon JM,
    5. Loncaster J,
    6. Hatton M

    , et al. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncol 2018; 19: 1516–1529.

    OpenUrl
23. 23.↵
    1. Parulekar WR,
    2. Berrang T,
    3. Kong I,
    4. Rakovitch E,
    5. Theberge V,
    6. Gelmon KA, et al.

    Cctg MA.39 tailor RT: a randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693). J Clin Oncol 2019; 37: TPS602.
24. 24.↵
    1. Boulle G,
    2. Saint-Martin C,
    3. De La Lande B,
    4. Laki F,
    5. Bidoz NF,
    6. Berger F, et al.

    Photons without bolus versus electrons with bolus after upfront mastectomy without Immediate reconstruction in breast cancer patients. Int J Radiat Oncol Biol Phys 2019; 104: 877–884.

    OpenUrl
25. 25.↵
    1. Nichol A,
    2. Raman S,
    3. Truong P,
    4. Lovedeep G,
    5. Speers C,
    6. Tran E, et al.

    The effect of bolus on local control for patients treated with mastectomy and adjuvant radiotherapy. Int J Radiat Oncol 2019; 105: S9.

    OpenUrl
26. 26.↵
    1. Borm KJ,
    2. Voppichler J,
    3. Düsberg M,
    4. Oechsner M,
    5. Vag T,
    6. Weber W, et al.

    FDG/PET-CT–Based lymph node atlas in breast cancer patients. Int J Radiat Oncol Biol Phys 2019; 103: 574–582.

    OpenUrl
27. 27.↵
    1. Ujaimi R,
    2. Awad N,
    3. Hasan Z,
    4. Abbas N,
    5. Baageel W,
    6. Khayyat S et al.

    Internal mammary lymph node volume: what radiation dose is received with modified wide tangents? Int j pharm phytopharm res 2020; 10: 76–81.

    OpenUrl
28. 28.↵
    1. Jethwa KR,
    2. Kahila MM,
    3. Hunt KN,
    4. Brown LC,
    5. Corbin KS,
    6. Park SS, et al.

    Delineation of internal mammary nodal target volumes in breast cancer radiation therapy. Int J Radiat Oncol Biol Phys 2017; 97: 762–769.

    OpenUrl
29. 29.
    1. Meattini I,
    2. Guenzi M,
    3. Fozza A,
    4. Vidali C,
    5. Rovea P,
    6. Meacci F, et al.

    Overview on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant radiotherapy for breast cancer. Breast Cancer 2017; 24: 52–62.

    OpenUrl
30. 30.↵
    1. Lewis GD,
    2. Farach A.

    Cardiovascular toxicities of radiation therapy. Methodist Debakey Cardiovasc J 2019; 15: 274–281.

    OpenUrl
31. 31.↵
    1. Chatterjee S,
    2. Chakraborty S,
    3. Moses A,
    4. Nallathambi C,
    5. Mahata A,
    6. Mandal S, et al.

    Resource requirements and reduction in cardiac mortality from deep inspiration breath hold (DIBH) radiation therapy for left sided breast cancer patients: A prospective service development analysis. Pract Radiat Oncol 2018; 8: 382–387.

    OpenUrl
32. 32.↵
    1. Simcock R,
    2. Thomas TV,
    3. Estes C,
    4. Filippi AR,
    5. Katz MA,
    6. Pereira IJ, et al.

    COVID-19: global radiation oncology’s targeted response for pandemic preparedness. Clin Transl Radiat Oncol 2020; 22: 55–68.

    OpenUrl
33. 33.↵
    1. Brunt AM,
    2. Haviland JS,
    3. Wheatley DA,
    4. Sydenham MA,
    5. Alhasso A,
    6. Bloomfield DJ, et al.

    Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicenter, non-inferiority, randomized, phase 3 trial. Lancet 2020; 395: 1613–1626.

    OpenUrlCrossRefPubMed